Aclaris Therapeutics Inc

8AT

Company Profile

  • Business description

    Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

  • Contact

    701 Lee Road
    Suite 103
    WaynePA19087
    USA

    T: +1 484 324-7933

    E: [email protected]

    https://www.aclaristx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    64

Stocks News & Analysis

stocks

Ask the analyst: Can this genius product create the next ASX software king?

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks

Impact of ANZ’s huge fine

Working to prevent repeated failures could also improve competitiveness.
stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,151.201.30-0.01%
CAC 407,818.2278.71-1.00%
DAX 4023,329.24419.62-1.77%
Dow JONES (US)45,751.78131.67-0.29%
FTSE 1009,195.6681.37-0.88%
HKSE26,438.518.05-0.03%
NASDAQ22,328.6420.10-0.09%
Nikkei 22544,902.27134.150.30%
NZX 50 Index13,234.8926.580.20%
S&P 5006,605.469.82-0.15%
S&P/ASX 2008,877.703.00-0.03%
SSE Composite Index3,861.861.360.04%

Market Movers